OFIXHealthcare · Medical DevicesThe 4 Wall Street analysts covering Orthofix Medical, Inc. hold a median 12-month price target of $13 — +43.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Orthofix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Momentum (21): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OFIX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +43.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $18 → $13 |
| 6 July 2026 | Barrington Research | Maintains | Outperform | $15 → $17 |
| 6 July 2026 | Barrington Research | Maintains | Outperform | — |
| 22 May 2026 | Barrington Research | Maintains | Outperform | — |
| 22 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 22 May 2026 | Stifel | Maintains | Buy | — |
| 10 Apr 2026 | Barrington Research | Maintains | Outperform | — |
| 9 Mar 2026 | Stifel | Maintains | Buy | — |
| 26 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 17 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 27 Jan 2026 | TD Cowen | Initiates | Hold | — |
| 5 Nov 2025 | Barrington Research | Maintains | Outperform | — |
| 28 Oct 2025 | Stifel | Reinstates | Buy | $22 |
| 23 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 23 June 2025 | Barrington Research | Initiates | Outperform | — |
| 6 June 2025 | JMP Securities | Reiterates | Market Perform | — |
| 26 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 26 Feb 2025 | Roth MKM | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OFIX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Orthofix Medical, Inc. returned −41.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 83% of US stocks
Cheaper than 74% of US stocks
Cheaper than 10% of US stocks
Higher than 37% of US stocks
Higher than 41% of US stocks
Higher than 83% of US stocks
Higher than 29% of US stocks
Higher than 21% of US stocks
Higher than 34% of US stocks
Higher than 35% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Orthofix Medical, Inc. has a market value of $369.4M and an enterprise value of $527.5M.
Revenue in the twelve months to 30 June 2026: $833.2M. The latest quarter grew 3.8% year on year.
Net income over the same four quarters: −$61.7M, a −7.4% net margin.
Diluted earnings per share, trailing twelve months: $−1.54.
Free cash flow in the twelve months to 30 June 2026: −$27.8M, after $44.1M of capital spending.
Trailing P/E: −3.9×; forward P/E: 24.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Orthofix Medical, Inc. employs 1,605 people — $519K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Orthofix Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Orthofix Medical said it will release its third-quarter 2026 financial results before market open on Monday, November 9, 2026. The company will host a conference call and webcast to review the results at 8:30 a.m. Eastern Time that day.
Why it matters — OFIX watchers may note the scheduled date and time to follow the company’s quarterly results and related management discussion.
Levi & Korsinsky announced that it has commenced an investigation of Orthofix Medical concerning possible breaches of fiduciary duties by certain officers and directors.
Why it matters — The investigation is a corporate-governance matter concerning Orthofix and may be relevant to shareholders following the company.
A PRNewsWire item asks Orthofix Medical shareholders to contact a law firm to discuss their rights and options concerning alleged insider breaches of fiduciary duties. The firm says there is no cost or obligation to discuss the matter and that it would work on a contingent-fee basis.
Why it matters — OFIX watchers may note the allegations and the outreach to shareholders, although the excerpt does not provide details about any legal action or findings.
Levi & Korsinsky announced an investigation into Orthofix Medical concerning possible breaches of fiduciary duties by certain officers and directors. The announcement invited current shareholders to request additional information.
Why it matters — The investigation concerns the conduct of Orthofix leadership and may be relevant to shareholders monitoring the company.
Orthofix Medical executives said the company's updated outlook reflects restored bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.
Why it matters — The revision shows a mix of supportive reimbursement and product-line tailwinds weighed against a weakening U.S. spine distribution channel, which directly bears on Orthofix's forward performance.
The 4 Wall Street analysts covering Orthofix Medical, Inc. have a median 12-month price target of $13, with estimates ranging from $12 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Orthofix Medical, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Orthofix Medical, Inc. 68 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Orthofix Medical, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +43.3% from the last close, and Ticker Nerd's factor model ranks Orthofix Medical, Inc. 68 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Orthofix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OFIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $14 over the next 12 months.
Orthofix Medical, Inc. returned -41.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Orthofix Medical Inc. is a global medical technology company focused on spine and orthopedic care.
The most recent item we track (Business Wire, 23 Oct 2026): "Orthofix to Report Third Quarter 2026 Financial Results". Orthofix Medical said it will release its third-quarter 2026 financial results before market open on Monday, November 9, 2026. The company will host a conference call and webcast to review the results at 8:30 a.m. Eastern Time that day.
Orthofix Medical Inc. is a global medical technology company focused on spine and orthopedic care. The company develops and markets a broad portfolio of spinal implants, bone growth therapies, biologics, and enabling technologies used by surgeons and healthcare providers to treat complex musculoskeletal conditions. Its product range also includes limb reconstruction and deformity correction solutions, as well as image-guided navigation systems that support surgical planning and execution. Orthofix Medical serves hospitals, ambulatory surgery centers, and medical specialists across multiple care settings, with products designed to address trauma, degenerative disorders, fracture management, and other orthopedic applications. Headquartered in Lewisville, Texas, Orthofix Medical plays a specialized role in the medical devices market by providing technology-driven solutions for reconstructive and regenerative musculoskeletal treatment.
CEO Mr. Massimo Calafiore · 1,605 employees · United States · https://orthofix.com
